(0.89%) 5 127.25 points
(0.22%) 38 373 points
(1.16%) 17 771 points
(0.51%) $84.00
(-2.08%) $1.604
(0.39%) $2 351.60
(1.05%) $27.64
(1.35%) $932.90
(0.04%) $0.932
(0.05%) $10.96
(0.02%) $0.799
(0.02%) $92.19
Live Chart Being Loaded With Signals
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids...
Stats | |
---|---|
Today's Volume | 28 189.00 |
Average Volume | 10 795.00 |
Market Cap | 14.35M |
EPS | $0 ( 2024-04-03 ) |
Next earnings date | ( $-0.120 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.540 |
ATR14 | $0.0710 (0.61%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-21 | Barbier Ann | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Geraghty James A | Buy | 45 000 | Stock Option (right to buy) |
2023-06-21 | Kiener Peter A | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Kiritsy Christopher P | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Richman Michael | Buy | 40 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
17.19 |
Last 97 transactions |
Buy: 6 636 987 | Sell: 4 508 050 |
Volume Correlation
Pieris Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pieris Pharmaceuticals Correlation - Currency/Commodity
Pieris Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $42.81M |
Gross Profit: | $41.03M (95.84 %) |
EPS: | $-0.270 |
Q4 | 2023 |
Revenue: | $1.30M |
Gross Profit: | $-3.16M (-242.88 %) |
EPS: | $-0.0463 |
Q3 | 2023 |
Revenue: | $19.52M |
Gross Profit: | $18.78M (96.21 %) |
EPS: | $-0.110 |
Q2 | 2023 |
Revenue: | $20.06M |
Gross Profit: | $19.33M (96.38 %) |
EPS: | $0.0454 |
Financial Reports:
No articles found.
Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators